Literature DB >> 24818767

Stimuli-sensitive nanopreparations for combination cancer therapy.

Aditi Jhaveri1, Pranali Deshpande1, Vladimir Torchilin2.   

Abstract

Nanocarriers have revolutionized drug delivery practices over the past couple of decades, primarily due to the advances in materials chemistry, nanotechnology and nanomedicine. This in turn, has spurred the development of a number of novel nanocarrier-based platforms and treatment strategies for cancer. It is now clear that to manage a disease as complex as cancer, a single or stand-alone treatment strategy may not suffice. Present day drug delivery strategies progressively lean towards "multi-pronged" combination approaches to make cancer treatments more effective. To that end, nanocarriers which simultaneously incorporate multiple drugs that affect different pathways and act through different mechanisms, or combinations of drugs with biological therapeutics like genes, antibodies, proteins or siRNAs have been the focus of recent active research. Furthermore, nanocarriers which respond to a variety of intrinsic cues afforded by the tumor microenvironment like low pH, elevated redox potential, over-expressed enzymes and hyperthermia as well as to externally applied stimuli such as magnetic field, ultrasound or light have been developed to trigger site-specific drug release. In this review, we focus specifically on nanocarriers that simultaneously exhibit stimuli-sensitivity and incorporate various combinations of conventional small molecule chemotherapeutic agents and biologics. We provide an overview of the different internal and external stimuli most relevant to cancer, and discuss selected examples of stimuli-sensitive combination nanopreparations from the recent literature with respect to each stimulus. Finally, we discuss multifunctional stimuli-sensitive nanopreparations which incorporate various combinations of drugs, biologics and targeting ligands within a single carrier that form so-called "smart" nanopreparations.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Co-delivery; Combination; Multifunctional; Nanoparticles; Stimuli-sensitive

Mesh:

Substances:

Year:  2014        PMID: 24818767     DOI: 10.1016/j.jconrel.2014.05.002

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  49 in total

Review 1.  Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.

Authors:  Samuel S Linton; Samantha G Sherwood; Kelly C Drews; Mark Kester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-07-07

Review 2.  Advances in the clinical translation of nanotechnology.

Authors:  David A Scheinberg; Jan Grimm; Daniel A Heller; Evan P Stater; Michelle Bradbury; Michael R McDevitt
Journal:  Curr Opin Biotechnol       Date:  2017-02-07       Impact factor: 9.740

3.  Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.

Authors:  Jingjing Sun; Yanhua Liu; Yichao Chen; Wenchen Zhao; Qianyu Zhai; Sanjay Rathod; Yixian Huang; Suoqin Tang; Yong Tae Kwon; Christian Fernandez; Raman Venkataramanan; Song Li
Journal:  J Control Release       Date:  2017-05-12       Impact factor: 9.776

4.  In vivo targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide.

Authors:  Dongzhi Yang; Liangzhu Feng; Casey A Dougherty; Kathryn E Luker; Daiqin Chen; Meagan A Cauble; Mark M Banaszak Holl; Gary D Luker; Brian D Ross; Zhuang Liu; Hao Hong
Journal:  Biomaterials       Date:  2016-07-26       Impact factor: 12.479

5.  Radio-nanomaterials for biomedical applications: state of the art.

Authors:  Weifei Lu; Hao Hong; Weibo Cai
Journal:  Eur J Nanomed       Date:  2016-02-06

6.  Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.

Authors:  Zhengxiong Li; Linlin Zhang; Cui Tang; Chunhua Yin
Journal:  Pharm Res       Date:  2017-09-25       Impact factor: 4.200

7.  Co-delivery of protein and small molecule therapeutics using nanoparticle-stabilized nanocapsules.

Authors:  Chang Soo Kim; Rubul Mout; Yunlong Zhao; Yi-Cheun Yeh; Rui Tang; Youngdo Jeong; Bradley Duncan; Jeanne A Hardy; Vincent M Rotello
Journal:  Bioconjug Chem       Date:  2015-04-30       Impact factor: 4.774

Review 8.  Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.

Authors:  Christopher M Hartshorn; Michelle S Bradbury; Gregory M Lanza; Andre E Nel; Jianghong Rao; Andrew Z Wang; Ulrich B Wiesner; Lily Yang; Piotr Grodzinski
Journal:  ACS Nano       Date:  2017-12-22       Impact factor: 15.881

9.  Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.

Authors:  Xuelei Yin; Yingying Chi; Chuanyou Guo; Shuaishuai Feng; Jinhu Liu; Kaoxiang Sun; Zimei Wu
Journal:  Pharm Res       Date:  2017-07-19       Impact factor: 4.200

10.  Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.

Authors:  Peng Zhang; Jiang Li; Mohammed Ghazwani; Wenchen Zhao; Yixian Huang; Xiaolan Zhang; Raman Venkataramanan; Song Li
Journal:  Biomaterials       Date:  2015-07-15       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.